Stressgen (VSE: SSB) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Stressgen (VSE: SSB)

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: james paterson who wrote (86)	3/4/1999 7:20:00 PM
From: Heat Shock	of 236

To all: what will be the indication(s) for the phase I trial(s) of the joint venture between StressGen and Genzyme Molecular Oncology (GZMO)? Today's GZMO press release, biz.yahoo.com apparently lists the candidates in the following paragraph: Genzyme Molecular Oncology has completed two phase I cancer vaccine trials in melanoma. These studies demonstrated that treatment with either the MelanA/Mart1 or the gp100 antigen was safe and well-tolerated. In addition, a number of patients showed significant tumor regression. Genzyme Molecular Oncology plans to initiate three additional clinical trials for cancer vaccines in 1999, including a phase I/II trial in melanoma, and phase I trials in breast cancer and ovarian cancer. Heat

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next